Groundbreaking Study Reveals RSV Vaccine Significantly Reduces Infant Hospitalization Rates A new study presented at ESCMID Global 2026 highlights the effectiveness of the RSV vaccine during pregnancy, indicating an 80% drop in infant hospitalizations from RSV.

Groundbreaking Study Reveals RSV Vaccine Significantly Reduces Infant Hospitalization Rates #United_Kingdom #Maternal_Health #RSV_Vaccine #München #UKHSA_Study

Clover Biopharmaceuticals Announces Promising Phase I Clinical Trial Results for RSV Vaccine Re-Vaccination in Older Adults Clover Biopharmaceuticals reveals new data from its Phase I trial showing a significant increase in RSV antibodies, boosting hopes for better elderly protection.

Clover Biopharmaceuticals Announces Promising Phase I Clinical Trial Results for RSV Vaccine Re-Vaccination in Older Adults #China #Shanghai #Clinical_Trials #RSV_Vaccine #Clover_Biopharmaceuticals

Clover Biopharmaceuticals Launches Phase 2 Trial for Novel Combination Vaccine Against RSV, hMPV, and PIV3 Clover Biopharmaceuticals has initiated a Phase 2 clinical trial for its innovative combination vaccine targeting RSV, hMPV, and PIV3, promising a significant leap in respiratory disease prevention.

Clover Biopharmaceuticals Launches Phase 2 Trial for Novel Combination Vaccine Against RSV, hMPV, and PIV3 #Shanghai #Australia #RSV_Vaccine #Phase_2_Trial #Clover_Biotech

Miller Children's & Women's Hospital Recognized for Excellence in Infant Immunization Efforts Miller Children's & Women's Hospital has once again received recognition for its outstanding commitment to infant immunization against RSV, underscoring its dedication to child health.

Miller Children's & Women's Hospital Recognized for Excellence in Infant Immunization Efforts #United_States #Long_Beach #RSV_Vaccine #Infant_Health #Miller_Hospital

Respiratory Syncytial Virus Market Expected to Surge to USD 4.54 Billion by 2033 with Innovative Vaccines and Antibody Developments The Respiratory Syncytial Virus market is set to expand significantly, reaching USD 4.54 billion by 2033, driven by advanced vaccines and monoclonal antibodies for prevention.

Respiratory Syncytial Virus Market Expected to Surge to USD 4.54 Billion by 2033 with Innovative Vaccines and Antibody Developments #United_States #Austin #Monoclonal_Antibodies #RSV_Vaccine #DataM_Intelligence

Clover Biopharmaceuticals Reveals Promising Phase I Data for Combination RSV Vaccines Clover Biopharmaceuticals shared encouraging Phase I trial results for their innovative combination RSV vaccines, which may significantly improve protection for older adults.

Clover Biopharmaceuticals Reveals Promising Phase I Data for Combination RSV Vaccines #China #Shanghai #RSV_Vaccine #Clover_Biopharma #PIV3_vaccine

Meijer Pharmacies Strengthen Health Programs with Expert Vaccine Offerings for Autumn Meijer Pharmacy is bolstering health initiatives by offering essential vaccines as autumn approaches, ensuring Midwest communities are protected.

Meijer Pharmacies Strengthen Health Programs with Expert Vaccine Offerings for Autumn #RSV_Vaccine #Meijer_Pharmacy #Pneumonia_Vaccine

Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates Clover Biopharmaceuticals has launched a Phase I clinical trial for SCB-1022 and SCB-1033, a promising combination vaccine for RSV, hMPV, and PIV3 aimed at addressing respiratory diseases.

Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates #China #Shanghai #RSV_Vaccine #Clover_Biopharma #Phase_I_Trials

Clover Biopharmaceuticals Receives IND Clearance for RSV Vaccine SCB-1019 and Starts Revaccination Study Clover Biopharmaceuticals has announced the U.S. IND clearance for its RSV vaccine candidate SCB-1019, marking the commencement of Phase I revaccination trials targeting older adults.

Clover Biopharmaceuticals Receives IND Clearance for RSV Vaccine SCB-1019 and Starts Revaccination Study #Shanghai #United_States #RSV_Vaccine #Clover_Biopharma #SCB-1019

Essential Vaccines to Keep Your Family Healthy This New Year As the new year begins, keeping your family healthy should be a priority. Vaccines for flu, COVID-19, and RSV can significantly reduce risks.

Essential Vaccines to Keep Your Family Healthy This New Year #United_States #Kansas #COVID-19_Vaccines #Flu_Vaccines #RSV_Vaccine